DUBLIN--(BUSINESS WIRE)--The "Insulin Resistance - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Insulin Resistance - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Insulin Resistance development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Insulin Resistance pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Insulin Resistance Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Insulin Resistance
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
-
Product Development Activities
Companies Mentioned
- Eisai Co Ltd
- Genentech
- ProMetic Life Sciences
- TWi Biotechnology
- Araim Pharmaceutical
- Aus Bio Limited
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wqgpwn/insulin?w=4
